Clinical trial
The Phase I Clinical Study of the Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine BMD006 in Patients With Advanced Lung Cancer or Metastatic Solid Tumors in the Lungs.
NCT06928922 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Phase I Clinical Study of the Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine BMD006 in Patients With Advanced Lung Cancer or Metastatic Solid Tumors in the Lungs.
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- February 24, 2025
- Completion date
- February 24, 2028
- Enrollment
- 83 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced lung cancer, lung metastasis